Baxter announces new research on 3-in-1 Oxiris filter Set for continuous renal replacement therapy and sepsis management.

axter International Inc. announced that the peer-reviewed journal Blood Purification published a supplemental issue sponsored by Baxter that features real-world clinical experience with the company’s Oxiris filter, which can be used simultaneously in continuous renal replacement therapy (CRRT) and in the removal of cytokines and endotoxin to aide in the management of acute kidney injury (AKI) patients with sepsis.

The studies, which are being highlighted at the 37th Vicenza Course on AKI and CRRT in Italy add to the body of scientific knowledge around the use of extracorporeal (outside the body) blood purification (EBP) to address critical conditions. The use of EBP to remove cytokines and endotoxin from the blood represents a promising approach to treat patients with conditions where excessive levels of those inflammatory mediators are often seen including sepsis, a serious medical condition that affects up to 40 percent of critically ill patients in the ICU.

While EBP continues to be studied for its potential to help address sepsis and other conditions, clinical research is particularly challenging in this setting. In fact, many clinical trials that explored the effect of EBP have failed to demonstrate consistent results due to the complexity of patient cases, among other factors. To help address these limitations.Baxter intends to support the creation of the OxirisNet registry with several Italian hospitals to track key treatment data for patients who receive a treatment with the Oxiris filter. The new registry will use a web-based platform specifically designed for research purposes and will be fed by clinical data that are prospectively collected.

Among the nine manuscripts published in the new Blood Purification supplement, clinicians described filter technologies available and shared clinical experiences when treating different types of patients. In one manuscript, researchers in Italy performed a retrospective observational study including 50 patients who were treated with CRRT (continuous renal replacement therapy) using the Oxiris set to address AKI and sepsis or septic shock. A second manuscript described a retrospective cohort study of 31 patients in France who had septic shock and AKI (acute kidney injury) requiring CRRT combined with Oxiris. Though their conclusions were limited by available data and study designs, the researchers observed an association between treatment with Oxiris and certain improved clinical measures, such as hemodynamic status (reduction in lactate level and norepinephrine dose and increase in mean arterial pressure) and renal function, providing an important evidence base for clinicians using Oxiris in current practice. Additional data is needed to validate these real-world outcomes. Baxter funded the logistics to publish and provide open access to the supplement and was involved in identifying its theme and potential contributors. However, manuscripts were independently reviewed and Baxter was not involved in creating the content except as contributing authors on certain manuscripts.

See- Blood Purification- Vol. 47, Suppl. 3, 2019- "Blood Purification Techniques in Sepsis and AKI" See also ISBN 978-3-318-06529-9 for more details Blood Purif 2019;47(suppl 3):I–III (DOI:10.1159/000500218).

Comment: Baxter International Inc.,launched a new indication for the company’s oXiris set in 2017, which can now be used to help remove excessive levels of cytokines, endotoxin and other inflammatory mediators from a patient’s blood. This makes oXiris the first blood purification set that can be used in continuous renal replacement therapy (CRRT) and sepsis management protocols. Previously, the oXiris set was only indicated for CRRT, which is a type of extracorporeal (outside the body) blood purification (EBP) used with Baxter’s Prismaflex system to manage patients with acute kidney injury.